I reckon that you are dead wrong about changing to a distributor only model worldwide. And I think that the sales figures to date demonstrate why you are wrong.
The best sales performances are coming from the direct sales territories, i.e., USA and ANZ.
The co went from distributor model in the USA just because it wasn't working fast enough. USA shows why the direct model, at least there, works extremely well. The co can control the quality and skills of its sales people. It can provide a laser-focused level of support that will ensure sales of BTM will continue to attract and hold surgeons.
You are correct about the importance of product development to the company and its skills in this, BUT, what you are missing is that by having direct contact with its customers the company is getting the kind of immediate feedback that is so valuable to product development.
So, in my view, shrinking its activities to R&D would be a very big mistake.
PNV Price at posting:
96.0¢ Sentiment: Buy Disclosure: Held
(20min delay)